Healey ALS Platform Trial - Regimen F ABBV-CLS-7262 | Clinical Research Studies Listing

Recruiting

18 years - 100 years

All

Phase 2

2 participants needed

1 Location

Brief description of study

ABBV-CLS-7262 is a prodrug that is converted in vivo to the pharmacologically active parent compound A-1684909. A-1684909 is a central nervous system (CNS)-penetrant, eukaryotic translation initiation factor 2B (eIF2B) activator that attenuates the integrated stress response (ISR), a highly conserved cellular mechanism hypothesized to be important in the pathophysiology of amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions when activated chronically (Costa-Mattioli et al. 2020).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Amyotrophic Lateral Sclerosis,ALS
Age: 18 years - 100 years
Gender: All

Confirmed ALS diagnosis; greater than 50% FVC or SVC; less than 36 months since symptom onset; must either be not taking, or on a stable dose of Riluzole, Edaravone (Radicava), or Relyvrio

Updated on 04 Aug 2024. Study ID: 842770F

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Healey ALS Platform Trial - Regimen F ABBV-CLS-7262

Brief description of study

Eligibility of study

Find a site

Interested in the study